Healthcare / BiotechnologyShenzhen
$12.00
+0.16 (+1.35%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 19%
FCF escenarios
weak_data · normalized FCF $231141.93 · quality 45.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.2B
P/E
171.4x
↑EV/EBITDA
56.4x
↑ROE
4.3%
↑Gross Margin
77.1%
↑Debt/Equity
0.22
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+0.9%
FCF CAGR
+3.8%
FCF margin
8.6%
FCF / Net income
1.37x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $387.7M · net income $24.3M · FCF $33.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $387.7M | $387.7M | $377.5M | $404.2M | $377.3M |
| Net Income | $24.3M | $24.3M | $27.4M | $31.0M | $-307.8M |
| EBITDA | $57.0M | $57.0M | $55.9M | $62.9M | $-255.4M |
| EPS | 0.09 | 0.09 | 0.10 | 0.12 | -1.16 |
| Gross Margin | 77.1% | 77.1% | 79.5% | 79.1% | 76.2% |
| Operating Margin | 9.1% | 9.1% | 14.2% | 13.7% | 13.0% |
| Net Margin | 6.3% | 6.3% | 7.3% | 7.7% | -81.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.22 | 0.22 | 0.20 | 0.11 | 0.16 |
| Current Ratio | 1.73 | 1.73 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $33.3M | $33.3M | $-26.6M | $231141.93 | $29.8M |
| Returns | |||||
| ROE | 4.3% | 4.3% | 5.1% | 6.0% | -63.4% |
| Valuation | |||||
| P/E | 171.43 | 171.43 | 121.10 | 111.08 | — |
| EV/EBITDA | 56.39 | 56.39 | 59.41 | 53.97 | — |
| P/B | 5.69 | 5.69 | 6.12 | 6.62 | 5.64 |
| Growth & Yield | |||||
| Revenue Growth | 2.7% | 2.7% | -6.6% | 7.1% | — |
| EPS Growth | -10.0% | -10.0% | -16.7% | 110.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
127.9%
EPS terminal req.
$1.06
Spread vs growth
-137.9%
5Y implied EPS CAGR
70.3%
EPS terminal req.
$1.29
Spread vs growth
-80.3%
10Y implied EPS CAGR
36.9%
EPS terminal req.
$2.07
Spread vs growth
-46.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-9.6%
Start / end P/E
132.8x → 133.3x
EPS bridge
0.10 → 0.09
Residual
-0.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.